Floatz logo

HUMAN ANTI-CXCR4 IGG4 MONOCLONAL ANTIBODY

Acute Myelogenous Leukemia

Bristol-Myers Squibbmonoclonal_antibodyPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
81/ 100

Competitive context

685 Active assets in the Acute Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB

View all 50 →

Same molecule, other indications

HUMAN ANTI-CXCR4 IGG4 MONOCLONAL ANTIBODY is also rated in:

diffuse large B-cell lymphomaDormant
CC
Indicative ·
44 / 100
View asset →
leukemiaDormant
C
Indicative ·
39 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →